

SUMMARY


In one aspect, the present disclosure refers to a use of a compound represented by the following structural formula:



Regioisomer-1 ,



Regioisomer-2 and



Regioisomer-3

or a pharmaceutically acceptable salt thereof; wherein:

R_1 is selected from hydrogen and alkyl;

R_2 is -A-R_4;

A is arylene or tetrasubstituted arylene; wherein the substituent is halogen;

R_3 is selected from hydroxy and amino;

R_4 is selected from an aryl and a heteroaryl that is optionally substituted with one or more R_5;

R_5 is selected from alkyl and -$(CH_2)_nN(R_a)R_b$;

R_a and R_b are independently selected from hydrogen, alkyl and –C(O)alkyl;

alternatively R_a and R_b can be taken together with the nitrogen atom to which they are attached to form a 4-6 membered heterocyclyl containing 0-2 additional heteroatoms independently selected from O and N and is optionally substituted with alkyl; and

n is an integer selected from 0 and 1,

in the manufacture of a medicament for treating a cancer selected from B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, lung cancer, melanoma, colon cancer, pancreatic cancer, bone cancer, cancer of the head or neck, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of


the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, and environmentally induced cancer in a subject.

The present disclosure is directed to a method for treating a cancer in a subject in need of such treatment. In one example, the cancer is selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, lung cancer, breast cancer, triple negative breast cancer, melanoma, glioblastoma, prostate cancer, colon cancer, pancreatic cancer, bone cancer, cancer of the head or neck, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancer, and a PTEN mutant cancer. In another example, the cancer is selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, triple negative breast cancer, melanoma, prostate cancer, and cancer of the esophagus. The method comprises the step of administering to the subject one or more times a therapeutically effective amount of at least one compound according to formula (I):


CLAIMS

WHAT IS CLAIMED IS:


1. Use of a compound represented by any one of the following structural formula:



Regioisomer-1 ,



Regioisomer-2 and



Regioisomer-3

or a pharmaceutically acceptable salt thereof; wherein:

R_1 is selected from hydrogen and alkyl;

R_2 is -A-R_4;

A is arylene or tetrasubstituted arylene; wherein the substituent is halogen;

R_3 is selected from hydroxy and amino;

R_4 is selected from an aryl and a heteroaryl that is optionally substituted with one or more R_5;

R_5 is selected from alkyl and -$(CH_2)_nN(R_a)R_b$;

R_a and R_b are independently selected from hydrogen, alkyl and –C(O)alkyl;

alternatively R_a and R_b can be taken together with the nitrogen atom to which they are attached to form a 4-6 membered heterocyclyl containing 0-2 additional heteroatoms independently selected from O and N and is optionally substituted with alkyl; and

n is an integer selected from 0 and 1,

in the manufacture of a medicament for treating a cancer selected from B-prolymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, follicular lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, lung cancer, melanoma, colon cancer, pancreatic cancer, bone cancer, cancer of the head or neck, skin cancer, cutaneous or intraocular malignant endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland,

cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lymphoma cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, and environmentally induced cancer in a subject.

2. The use according to claim 1, wherein the cancer is selected from B-prolymphocytic leukemia, non-Hodgkin’s lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, melanoma, and cancer of the esophagus.

3. The use according to any one of claims 1 and 2, wherein the cancer is B-prolymphocytic leukemia.

4. The use according to any one of claims 1 and 2, wherein the cancer is non-Hodgkin’s lymphoma.

5. The use according to any one of claims 1 and 2, wherein the cancer is diffuse large B cell lymphoma.









6. The use according to any one of claims 1 and 2, wherein the cancer is anaplastic large cell lymphoma.







7. The use according to any one of claims 1 and 2, wherein the cancer is mantle cell lymphoma.


8. The use according to any one of claims 1 and 2, wherein the cancer is melanoma.

9. The use according to any one of claims 1 and 2, wherein the cancer is cancer of the esophagus.


10. The use according to any one of claims 1-9, wherein the compound is selected from:


,

,

,

,

,

,

,

,



,

,

,

,

,

,


HO
O
N
N
N
N
O


,


HO
O
N
N
N
N
O





,



O
OH
N
N
N
N

,



O
OH
N
N
N
N
O

,



HO
O
N
N
N
F
F
F
F
,

O
OH
N
N
N
N
,

O
OH
N
N
N
N
,

HO
O
N
N
N
N
N
,


HO
O
N
N
N
N


,


HO
O
F
F
F
F
N
N
N


,


HO
O
N
N
N
N
O


,


HO
O
N
N
N
N
O


,


HO
O
N
N
N
N


,


HO
O
N
N
N
N







,



O
OH
N
N
N
N
N


,



HO
O
N
N
N
N
N


,


,

,

,

,

,

,



,



,




, and


or a pharmaceutically acceptable salt thereof.

11. The use according to any one of claims 1-10, wherein the compound is




or a pharmaceutically acceptable salt thereof.

12. The use according to any one of claims 1-10, wherein the compound is




or a pharmaceutically acceptable salt thereof.

13. The use according to any one of claims 1-10, wherein the compound is




or a pharmaceutically acceptable salt thereof.

14. The use according to any one of claims 1-10, wherein the compound is




or a pharmaceutically acceptable salt thereof.

15. The use according to any one of claims 1-10, wherein the compound is



or a pharmaceutically acceptable salt thereof.

16. The use according to any one of claims 1-10, wherein the compound is



or a pharmaceutically acceptable salt thereof.